Judge Tosses Expert Testimony From Celebrex Case

Law360, New York (November 19, 2007, 12:00 AM EST) -- A federal judge has refused to allow expert testimony in the multidistrict product liability litigation that connects Pfizer Inc.’s anti-inflammatory drug Celebrex, in its most common dosage, with increased risks of heart attack and stroke.

On Monday, Judge Charles Breyer of the U.S. District Court for the Northern District of California ruled that the plaintiffs' experts' testimony had not “presented scientifically reliable evidence” that the 200 mg daily dose of Celebrex causes heart attacks and strokes. However, Judge Breyer denied all other requests from Pfizer and...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.